Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Poplawska, A." wg kryterium: Wszystkie pola


Wyświetlanie 1-2 z 2
Tytuł:
Body mass analysis in patients with Hashimoto thyroiditis
Autorzy:
Popławska-Kita, A.
Siewko, K.
Telejko, B.
Kościuszko-Zdrodowska, M.
Hryniewicka, J.
Szelachowska, M.
Milewski, R.
Górska, M.
Powiązania:
https://bibliotekanauki.pl/articles/1916450.pdf
Data publikacji:
2014
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
thyroid
thyroiditis
body mass index
thyrotropin
Opis:
Introduction: Hashimoto thyroiditis (HT) is one of the most common autoimmune thyroid disorders and o the most common cause of hypothyroidism, but the relation between TSH and body mass is still unclear. Material and methods: The group studied consisted of 53 patients with HT in euthyreosis and 28 healthy individuals. All the patients underwent thyroid ultrasonography and body mass analysis with the use of a medical analyzer INBODY 200. Blood samples were also analyzed for TSH and anti-thyroid antibodies. Results: The patients with HT had higher body mass (p=0.008), body mass index (BMI) (p=0.02), Waist-Hip Ratio (WHR) (0.01) and fat mass (p=0.02) than had the controls. In HT group increased body mass was observed in 72% of the patients (overweight in 38% and obesity in 35% of them), as compared with 38% of overweight/obesity in the control group. Thyroid volume was significantly lower (p=0.01) and anti-peroxidase antibodies level was two times higher in the group with the treatment period > 2 years, but the patients with relatively short treatment period were 7 kg heavier and their fat mass was 6 kg higher than in the subjects treated longer than 2 years. Conclusions: Our results suggest that the patients with HT, even in euthyreosis, have significantly higher body mass, BMI, WHR and fat mass than healthy individuals, which is probably associated with previous disturbances that led to the increase in fat mass at the stage of hypothyroidism. The observed changes tend to normalize during L-thyroxine replacement therapy.
Źródło:
Progress in Health Sciences; 2014, 4, 1; 18-23
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
PRRT as an alternative method of treatment in patient with glucagonoma syndrome: A case report
Autorzy:
Popławska-Kita, A.
Szyszkowska, A.
Brelska, P.
Kowalczuk, M.
Szostek, A.
Popławski, Ł.
Siewko, K.
Szelachowska, M.
Kamiński, G.
Werel, D.
Górska, M.
Powiązania:
https://bibliotekanauki.pl/articles/1917699.pdf
Data publikacji:
2016
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Glucagonoma
tumor
peptide receptor radionuclide therapy
Opis:
Introduction: Glucagonoma is a rare pancreatic neuroendocrine tumor derived from alpha-cells of the islet of Langerhans. Due to oversecretion of glucagon it is associated with a characteristic paraneoplastic phenomenon, called glucagonoma syndrome, which consists of necrolytic migratory erythema (NME), weight loss, diabetes mellitus, diarrhea, normochromic normocytic anemia, deep vein thrombosis or pulmonary embolism and neuropsychiatric disturbances. Treatment modalities include surgical removal of tumor, somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Case report: We present a case of 61-year-old woman diagnosed with glucagonoma in April 2012. Initially, body-caudal pancreatomy and resection of regional lymph nodes were performed. Five months after surgery, a PET-CT scan detected pathological mass with expression of somatostatin receptors in pancreatic body and metastases to regional lymph nodes. What is more, since April 2014 the patient had complained about persistent pruritus of the entire body. At present, due to the nonsurgical pancreatic mass and metastases she is treated with somatostatin analogs and PRRT. During this therapy the pruritus had decreased and currently there is no sign of cutaneous disease. Moreover, reduction of tumor size was obtained. Conclusions: PRRT may reduce tumor size and by reducing bothersome symptoms substantially improve the quality of life in patients with SSTR-positive tumors
Źródło:
Progress in Health Sciences; 2016, 6(1); 209-214
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies